AYUN.

What AYUN actually is

Switzerland’s first walk-in longevity clinic, opened in Zürich in 2023. The proposition is access — a storefront format where readers can buy individual diagnostic tests and treatment sessions rather than committing to a packaged programme tier. The model lowers the entry price meaningfully: a TruDiagnostic biological-age test plus consultation runs at a fraction of the cost of an Evolve-tier outpatient day.

This is, on its own terms, a useful addition to the category. The threshold price for engaging with longevity medicine has been too high, and AYUN’s modular structure is the right answer to that problem.

What you get

The diagnostic offering centres on TruDiagnostic’s OMICm Age — the epigenetic clock developed in collaboration with Harvard — plus advanced blood analysis, genetic testing, body composition, and functional assessment. The biological-age work is genuinely research-grade.

The treatment menu — hyperbaric oxygen, whole-body cryotherapy at -110°C, intermittent hypoxic-hyperoxic training (IHHT), IV nutrient infusions — is where the practice’s revenue centre of gravity sits. Sessions are bookable individually.

Lifestyle and nutrition coaching is included in most diagnostic intakes; the multidisciplinary team includes longevity specialists alongside the medical staff.

Where it sits in the directory

AYUN is the right purchase for a specific reader: someone who wants to start with longevity-relevant diagnostics, locally and at low commitment, before deciding whether to invest in the deeper workups at the upper tier.

For that reader, the OMICm biological age plus advanced bloodwork plus a consultation is a credible first baseline — it will identify the markers that justify (or do not justify) a deeper Evolve-tier or residential investment.

For the reader who is already past that first decision and wants the deepest workup the category can produce, AYUN is not it. The directory leaders run substantially more diagnostic depth and substantially less treatment-product pressure.

Where it falls short on evidence

Two specific points worth naming.

The evidence base for IHHT — intermittent hypoxic-hyperoxic training — in healthy adults is materially thinner than the marketing implies. The mechanism is interesting; the randomised data on healthspan-relevant outcomes in non-hypoxia-stressed populations is sparse.

Hyperbaric oxygen for non-clinical longevity indications sits in similar territory. The evidence for clinical indications (diabetic ulcers, decompression illness, certain stroke recovery) is robust; the evidence for healthy-population longevity benefit is preliminary.

We credit AYUN for offering these treatments transparently, with patient consent and clinician explanation. The marketing copy is more confident than the evidence currently supports.

The verdict

A useful entry point. Not a directory leader. Worth knowing about for the regional reader testing the category at lower commitment, particularly the biological-age work.

A clinic that lowers the entry price for serious diagnostics is, on balance, good for the field. A clinic that ladders into treatments with thin evidence is a different proposition. AYUN is both.